5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

Abstract Background Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. Methods In this multicenter, prospective, observational study of adults treated with...

Full description

Bibliographic Details
Main Authors: Reiko Matsui, Kenichi Suzuki, Tomomi Takiguchi, Makoto Nishio, Takeshi Koike, Toshinobu Hayashi, Takashi Seto, Yuki Kogure, Naoyuki Nogami, Kimiko Fujiwara, Hiroyasu Kaneda, Tomohiko Harada, Satoru Shimizu, Masashi Kimura, Hirotsugu Kenmotsu, Mototsugu Shimokawa, Koichi Goto
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Pharmacology and Toxicology
Subjects:
Antiemetic therapy
Chemotherapy-induced nausea and vomiting (CINV)
Moderate emetic risk chemotherapy (MEC)
NK-1 receptor antagonist
5-HT3 receptor antagonist
Online Access:http://link.springer.com/article/10.1186/s40360-020-00445-y

Internet

http://link.springer.com/article/10.1186/s40360-020-00445-y

Similar Items